Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.
about
Heart failure with preserved ejection fraction: emerging drug strategiesTargeting heart failure with preserved ejection fraction: current status and future prospectsA Review of Nebivolol Pharmacology and Clinical EvidenceNitric oxide synthases in heart failureExercise intolerance in heart failure with preserved ejection fraction: more than a heart problemHeart failure with preserved ejection fraction: mechanisms, clinical features, and therapiesPatient selection in heart failure with preserved ejection fraction clinical trialsAdvances in the management of heart failure: the role of ivabradineVericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) studyDeveloping therapies for heart failure with preserved ejection fraction: current state and future directionsTargeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trialsEffects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials.A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fractionLeft ventricular markers of global dyssynchrony predict limited exercise capacity in heart failure, but not in patients with preserved ejection fraction.Effect of Nebivolol on MIBG Parameters and Exercise in Heart Failure with Normal Ejection FractionCentral cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fractionβ3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failureA meta-analysis of the effects of β-adrenergic blockers in chronic heart failureCurrent treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?Pathological ventricular remodeling: therapies: part 2 of 2.Heart failure with preserved ejection fraction in the elderly: scope of the problem.Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure.Heart failure with normal ejection fraction: current diagnostic and management strategies.Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.Heart failure with preserved ejection fraction: a clinical dilemma.Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis.Pharmacotherapy of heart failure with preserved ejection fraction.Influence of vascular function and pulsatile hemodynamics on cardiac function.Intercellular communication lessons in heart failure.Heart Failure with Preserved Ejection Fraction in Older Adults.Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians.Myocardial reverse remodeling: how far can we rewind?Relations Between Aortic Stiffness and Left Ventricular Mechanical Function in the Community.Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial.Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction.Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter.[Diastolic heart failure: heart failure with preserved ejection fraction].
P2860
Q24595118-2929F6C5-E292-49AB-B151-B8B1DF821DF1Q26752956-B760A041-9DEB-40D9-B421-4E2E28E5B01FQ26801287-AEC1F941-0BF6-447C-AB36-6B49A4960BBAQ26830146-FA0EC55F-C7EA-46BC-8BAE-C7C05D498864Q26991985-7097F518-5B02-4582-ADDA-88E1ABE55DE5Q27000263-46DBE8DB-1A26-4783-BD22-708A34913CE7Q27015845-B7CB6936-4BD9-4617-BE9A-BF1A1D27CD0AQ28072418-CAD34156-A02A-4116-8F93-906F5D30BDA6Q33589713-1CCCC5B8-66E3-4417-8BD6-AFD42048F605Q33639223-60D75BA2-6126-454C-9A5A-329E5E8F2579Q33863759-33645B63-0697-4612-82B9-B08B696B9F5CQ34815329-2C1ADE3B-84CA-4A86-8AAB-6EE0A7B439D5Q35018046-A070E99C-D31F-4354-B30B-11D7F52AA7ABQ35057999-E68B2D04-BD55-458F-AD93-28F159939F36Q36498711-E953BE52-B72C-4CAB-B2FA-0823B75AAE00Q37021322-B21942EC-0CCA-4719-877D-01CE02C6A786Q37074089-2E5108A5-E5AF-4FED-8852-03E0803BF28EQ37142802-2D7548C6-A021-4B47-9C32-F284057E841AQ37289514-CC15657A-066B-4DAF-A90C-54EFE5E59CF9Q37292234-260510F1-7B3A-49A5-BE52-B7DFA42AF4AEQ37312758-1F70125B-7B95-4D0D-9BAF-63F7E083C2DAQ37633991-E54BF50E-5036-46EA-9056-AC447282C4F9Q37680383-F71539AA-7D47-4EC8-A87E-C84C67A8ED27Q38131062-4F15AAC2-9769-44F3-9E3B-B6A38C306A6FQ38134311-32F1F61B-A58D-4C80-BBED-604609ADE6EEQ38195149-E183545C-9E4B-4AF9-A9C6-A19A5535BC91Q38230776-42A98C94-0C2C-44A2-AE71-82D847E50244Q38425861-BF553179-2FB9-4AB7-A0F8-9A42D7A25F1BQ38545379-D409DDD2-C3A8-40BC-B682-5062A61BDDE4Q38591546-4C992E16-BBA9-484E-8716-832FE0E1CEB1Q38672337-DB3A5B8A-56F6-4B5C-BD58-322FEA7B37F5Q38743215-ED3A5601-35AC-45AF-B1F7-3B59A55BFD4BQ38768799-B7AFE91E-C144-4146-B25A-C69EB003E198Q38780883-3F09D424-2B38-40EF-91F4-F040C7506EB1Q40388462-6A60194F-49FC-4C43-B61B-CF38CCBB06ACQ41250771-E8EF53F8-42EE-4357-84E2-C1525588591FQ42058678-5F2399C4-7595-442F-A88A-F0CA1979C51FQ42393093-4C474716-19D5-4459-90F4-0F652AC9B555Q42863346-35EE0CDF-7BEA-4FA6-9CCB-A9BCD5061090Q45393684-4DE11D2B-BAAD-4EBF-969F-541597F8EE7F
P2860
Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Effects of the long-term admin ...... : results of the ELANDD study.
@en
Effects of the long-term admin ...... : results of the ELANDD study.
@nl
type
label
Effects of the long-term admin ...... : results of the ELANDD study.
@en
Effects of the long-term admin ...... : results of the ELANDD study.
@nl
prefLabel
Effects of the long-term admin ...... : results of the ELANDD study.
@en
Effects of the long-term admin ...... : results of the ELANDD study.
@nl
P2093
P2860
P50
P356
P1476
Effects of the long-term admin ...... : results of the ELANDD study.
@en
P2093
José Zamorano
Livio Dei Cas
Michael Böhm
Panos E Vardas
P2860
P304
P356
10.1093/EURJHF/HFR161
P577
2011-12-06T00:00:00Z